Ardelyx (NASDAQ:ARDX) Earns Buy Rating from HC Wainwright

Ardelyx (NASDAQ:ARDX)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a report released on Friday, Benzinga reports. They presently have a $11.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 80.62% from the stock’s previous close. HC Wainwright also issued estimates for Ardelyx’s Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at $0.01 EPS and FY2026 earnings at $0.58 EPS.

Several other research analysts also recently commented on ARDX. StockNews.com upgraded Ardelyx from a “sell” rating to a “hold” rating in a report on Wednesday, July 31st. Citigroup raised their price objective on Ardelyx from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Finally, Wedbush restated an “outperform” rating and set a $11.00 price objective on shares of Ardelyx in a report on Friday, August 2nd. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $11.67.

Ardelyx Trading Up 3.7 %

Shares of ARDX stock opened at $6.09 on Friday. Ardelyx has a 1 year low of $3.43 and a 1 year high of $10.13. The company has a debt-to-equity ratio of 0.68, a current ratio of 4.21 and a quick ratio of 3.99. The stock’s 50 day simple moving average is $6.07 and its two-hundred day simple moving average is $6.32. The company has a market cap of $1.43 billion, a PE ratio of -22.55 and a beta of 0.90.

Ardelyx (NASDAQ:ARDX) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.04. Ardelyx had a negative return on equity of 39.73% and a negative net margin of 31.02%. The firm had revenue of $73.20 million for the quarter, compared to the consensus estimate of $55.03 million. During the same period in the prior year, the business posted ($0.08) earnings per share. The company’s revenue for the quarter was up 228.3% on a year-over-year basis. Research analysts predict that Ardelyx will post -0.25 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Michael Raab sold 35,000 shares of the firm’s stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $5.61, for a total value of $196,350.00. Following the completion of the transaction, the chief executive officer now owns 1,220,608 shares in the company, valued at $6,847,610.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, CEO Michael Raab sold 35,000 shares of the firm’s stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $5.61, for a total value of $196,350.00. Following the completion of the transaction, the chief executive officer now owns 1,220,608 shares in the company, valued at $6,847,610.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider David P. Rosenbaum sold 49,564 shares of Ardelyx stock in a transaction dated Friday, September 27th. The shares were sold at an average price of $6.92, for a total value of $342,982.88. Following the transaction, the insider now owns 301,946 shares of the company’s stock, valued at $2,089,466.32. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 212,126 shares of company stock worth $1,298,963 in the last 90 days. Insiders own 5.90% of the company’s stock.

Hedge Funds Weigh In On Ardelyx

A number of institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Ardelyx by 2.8% in the 1st quarter. Vanguard Group Inc. now owns 13,391,855 shares of the biopharmaceutical company’s stock valued at $97,761,000 after purchasing an additional 365,809 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Ardelyx by 68.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,913,863 shares of the biopharmaceutical company’s stock valued at $28,572,000 after purchasing an additional 1,584,597 shares in the last quarter. Millennium Management LLC increased its stake in shares of Ardelyx by 142.8% in the 2nd quarter. Millennium Management LLC now owns 3,203,090 shares of the biopharmaceutical company’s stock valued at $23,735,000 after purchasing an additional 1,883,995 shares in the last quarter. Redmile Group LLC purchased a new position in shares of Ardelyx in the 1st quarter valued at about $16,020,000. Finally, Hennion & Walsh Asset Management Inc. increased its stake in shares of Ardelyx by 9.5% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 643,912 shares of the biopharmaceutical company’s stock valued at $4,437,000 after purchasing an additional 55,720 shares in the last quarter. Hedge funds and other institutional investors own 58.92% of the company’s stock.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.